Paxlovid not linked to COVID-19 rebound, FDA says ahead of meeting to consider drug's full approval

Over 8 million people in the U.S. have received Paxlovid, a combination of the drugs nirmatrelvir and ritonavir, since it became available under emergency use authorization in December 2021.